Form 4: Core Scientific Officer Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. officer Todd Duchene sold shares of common stock valued at approximately $230,000 through a pre-arranged trading plan.

Summary

• Todd Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc. (CORZ), reported the sale of 9,600 shares of common stock on May 18, 2026.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025.
• The shares were sold at a weighted average price of $23.1244, with individual transactions ranging from $22.66 to $23.62.
• Following these transactions, Duchene beneficially owns 1,960,748 shares of common stock.
• An additional 400 shares were sold at a weighted average price of $23.7575, with individual transactions ranging from $23.69 to $23.82.
• After this second set of sales, Duchene beneficially owns 1,960,348 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, although it was conducted under a pre-planned trading strategy.

Negatives

• Officer Todd Duchene sold a significant number of shares (9,600 and 400) of Core Scientific, Inc. common stock.
• The sales represent a reduction in direct beneficial ownership by a key executive.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.66 to $23.62, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.82, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under Rule 10b5-1 plans, are common for executives managing their personal finances and diversifying holdings. However, significant sales can sometimes be interpreted by the market as a lack of confidence in near-term stock performance, depending on the volume and the executive's role.

Stakeholder Impact

• Shareholders may view the executive's sale of stock as a potential signal, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees with stock options or grants may be sensitive to executive selling activity.

Key Dates

Recommendation

The sale was executed under a pre-established Rule 10b5-1 plan, indicating it was likely planned in advance and not based on recent material non-public information. While insider selling can be a negative signal, the structured nature of this transaction suggests it's more for personal financial management than a reflection of company outlook. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Core Scientific, CORZ, Form 4, insider trading, Rule 10b5-1, stock sale, executive compensation, beneficial ownership